SNMMI logo SNMMI-TS 50 Years Logo
Donate | Join/Renew | Store | View Cart | Log In
Search SNMMI.org
Search SNMMI Learning Center
Value Initiative | Physicians | Technologists | Scientists | Residents | Healthcare Provider | Patients
Toggle menu
  • NEWS & PUBLICATIONS
    • News and Media
    • Newsletters
    • Journals
    • Books
  • MEMBERSHIP
    • Join/Renew
    • Benefits
    • Categories
    • Download a Member Application
    • Grants, Awards, and Scholarships
    • Access the Phantom Analysis Toolkit
    • Membership Directory
    • Chapters
    • Centers of Excellence
    • Councils
    • Member Spotlight
    • Women in Nuclear Medicine
    • SNMMI Fellow
    • Council and Center Internships
  • EDUCATION
    • 2021 Annual Meeting Call for Abstracts
    • Webinars
  • MEETINGS & EVENTS
    • Calendar of Events
    • Webinars
    • 2021 Mid-Winter Meeting
    • 2021 Annual Meeting
    • Nuclear Medicine & Molecular Imaging Week
    • SNMMI-TS Leadership Academy
    • SNMMI Future Leaders Academy
  • ADVOCACY
    • Coding & Reimbursement
    • Legislative Efforts
    • Government Relations News
    • Radiopharmaceutical Supply News
    • USP 825
    • Technologist State Issues
    • Position Statements
    • Coalition for PET Drugs
    • FDA PET Drug Manufacturing Q&A
  • EVIDENCE & QUALITY
    • Clinical Guidelines and AUC
    • Quality
    • Practice Resources
    • Dose Optimization
    • About Quality & Practice
    • Dosimetry
  • RESEARCH
    • Clinical Trials Network
    • Radiopharmaceutical Therapy Central
    • Preclinical Imaging
    • Nuclear Medicine Clinical Trial Group, LLC
    • Research: Learn More
  • ABOUT SNMMI
    • Strategic Plan
    • Bylaws & Procedures
    • Governance - SNMMI
    • Governance - SNMMI-TS
    • History
    • Grants, Awards, and Scholarships
    • Annual Reports
    • Career Center
    • About Nuclear Medicine & Molecular Imaging
    • International Collaboration
    • Outreach
    • Support SNMMI
    • Contact Us
HOME > RESEARCH > Radiopharmaceutical Therapy Central

In This Section

  • Clinical Trials Network
    • About Us
    • Education Program
    • Scanner Validation Program
    • Site Qualification and Monitoring
    • Site Registry
    • Technologist Resources
    • Centralized Radiopharmaceutical INDs
  • Radiopharmaceutical Therapy Central
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
Advertisement

Education

Site prep thumbnail Site Preparation for Establishing 177Lu-Radioligand Therapy Programs

PET drug thumbnail There's a New PET Drug in Town: Manufacturing and Approval Consideration for Your Institution

FDA Categorical THERANOSTICS: Regulatory Considerations for Product Development

3trt image SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019

Guidance Documents

Site prep thumbnail Charging for Investigational Drugs Under an IND - Questions and Answers
Guidance for Industry - June 2016

PET drug thumbnail Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Guidance for Industry - June 2016

Therapy Implementation Checklist

RPT Toolkit Checklist (Adobe PDF)

RPT Toolkit Checklist (MS Word)

Publications

Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division

For more articles on nuclear medicine therapy from SNMMI journals, click here.

Technologists' Tools

Site prep thumbnail Nuts and Bolts on New Targeted Radionuclide Therapies: 177Lu-PSMA for Prostate Cancer

Technologist Quarterly Webinar: Lutetium Lu 177 Dotatate Administration in the Nuclear Medicine Department

Clinical Trials Network Webinar Series: Review of Radiopharmaceuticals Used in or for Radionuclide Therapy

ADVERTISING • LIST SALES • MEDIA • CONTACT • SITE MAP • PRIVACY NOTICE/LEGAL/DISCLAIMER COI • REPORT A PROBLEM
1850 Samuel Morse Drive  Reston, Virginia 20190  P: 703.708.9000  F: 703.708.9015
Download Acrobat Reader
STAY IN TOUCH: